The development of potential antibody-based therapies for myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The development of potential antibody-based therapies for myeloma

Published:2015-03 Issue:2 Volume:29 Page:81-91
ISSN:0268-960X
Container-title:Blood Reviews
language:en
Short-container-title:Blood Reviews

Author:

Sherbenou Daniel W.,Behrens Christopher R.,Su Yang,Wolf Jeffrey L.,Martin Thomas G.,Liu Bin

Funder

UCSF Stephen and Nancy Grand Multiple Myeloma Translational Initiative

National Institutes of Health/National Cancer Institute

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference112 articles.

1. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma;Molina;Annu Rev Med,2008

2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia;Plosker;Drugs,2003

3. Development trends for human monoclonal antibody therapeutics;Nelson;Nat Rev Drug Discov,2010

4. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma;Younes;J Clin Oncol Off J Am Soc Clin Oncol,2012

5. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study;Pro;J Clin Oncol Off J Am Soc Clin Oncol,2012

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-CD20 antibody treatment for B-cell malignancies;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024

2. Anti-BCMA novel therapies for multiple myeloma;Cancer Drug Resistance;2023

3. CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments;Frontiers in Immunology;2022-07-22

4. BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy;Drugs;2022-04

5. HDP-101, an Anti-BCMA Antibody–Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells;Molecular Cancer Therapeutics;2020-12-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3